#pharma #ulcerativecolitis
Lung cancer, Adenocarcinoma, Tobacco smoking, Cancer, Metastasis, Cancer staging

GSK suffers another R&D setback, axing ulcerative colitis drug trial

On Jan 25, 2021
@pharmaphorum shared
GlaxoSmithKline has suffered another research setback after it axed a phase 2 trial of an anti-LAG3 drug in patients with #ulcerativecolitis following a major disappointment with a key lung cancer drug last week https://t.co/utga1T1W6u #pharma
Open

GlaxoSmithKline has suffered another research setback after it axed a phase 2 trial of an anti-LAG3 drug in patients with ulcerative colitis, following a major disappointment with a key lung cancer drug last week.

pharmaphorum.com
On Jan 25, 2021
@pharmaphorum shared
GlaxoSmithKline has suffered another research setback after it axed a phase 2 trial of an anti-LAG3 drug in patients with #ulcerativecolitis following a major disappointment with a key lung cancer drug last week https://t.co/utga1T1W6u #pharma
Open

GSK suffers another R&D setback, axing ulcerative colitis drug trial

GSK suffers another R&D setback, axing ulcerative colitis drug trial

GlaxoSmithKline has suffered another research setback after it axed a phase 2 trial of an anti-LAG3 drug in patients with ulcerative colitis, following a major disappointment with a key ...

GSK, German Merck's $4.2B bintrafusp alfa drug a bust, fails to beat king Keytruda in lung cancer

GSK, German Merck's $4.2B bintrafusp alfa drug a bust, fails to beat king Keytruda in lung cancer

A drug that Pfizer passed over but saw a revitalized cancer R&D-focused GlaxoSmithKline jump on for $4.2 billion has come up as a dud in a key trial pitting it against U.S. Merck’s ...

Merck KGaA, GSK suffer lung cancer drug setback

Merck KGaA, GSK suffer lung cancer drug setback

Merck KGaA's drug development programme has suffered a setback with its most important experimental drug, cancer treatment bintrafusp alfa, failing early in its lead trial.

GlaxoSmithKline's $4B bispecific cancer drug alliance with Merck KGaA hit by big setback with a PhIII failure on NSCLC

GlaxoSmithKline's $4B bispecific cancer drug alliance with Merck KGaA hit by big setback with a PhIII failure on NSCLC

Close to 2 years ago, GSK’s R&D team eagerly agreed to pay up to $4 billion-plus to ally itself with Merck KGaA on a mid-stage bispecific called bintrafusp alfa, which intrigued them with ...

ASCO: Forget lung cancer history. Merck's Keytruda shatters the stats on long-term survival

ASCO: Forget lung cancer history. Merck's Keytruda shatters the stats on long-term survival

Before the dawn of immunotherapy, long-term survival was almost a foreign concept in the metastatic lung cancer arena. But Saturday, that’s just what Merck showed its Keytruda could produce.

Oncology, dermatology, hematology pace Q1 biopharma licensing

Oncology, dermatology, hematology pace Q1 biopharma licensing

However, the total deal value for the first quarter of the year was the highest ever for the same period over the last five years (see Figure 1), led by AstraZeneca and Daiichi Sankyo’s ...

Top 20 Pharma Companies by Market Cap in Q1 2019

Top 20 Pharma Companies by Market Cap in Q1 2019

GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.

Roche unveils first data for new type of cancer immunotherapy

Roche unveils first data for new type of cancer immunotherapy

Study results for a new type of checkpoint inhibitor were mixed, offering signs of promise as well reasons for caution.

Merck's new immunotherapy target

Merck's new immunotherapy target

#COYS Merck unveiled the first clinical data on a new type of antibody drug that targets myeloid cells, a type of immune cell that can suppress the immune system, limiting its ability to ...

Novo Seeds Portfolio Company IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Trial in First Line Non-small Cell Lung Cancer

Novo Seeds Portfolio Company IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Trial in First Line Non-small Cell Lung Cancer

Data position the company to start potential registrational trials with two drugs in two tumor types Copenhagen, Denmark, 25 February 2020 – Novo Seeds, the early stage ...

Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More

Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More

As the nation started to reopen this week following two months of closed businesses and stay-at-home orders, public health officials and economists

FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer

FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer

Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the US Approval based on the Phase III IMpower110 study showing ...